These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26039556)

  • 1. Afatinib (Gilotrif) for advanced non-small cell lung cancer.
    Med Lett Drugs Ther; 2015 May; 57(1469):e82-3. PubMed ID: 26039556
    [No Abstract]   [Full Text] [Related]  

  • 2. Gefitinib Approved for EGFR-Mutated NSCLC.
    Cancer Discov; 2015 Sep; 5(9):896. PubMed ID: 26238462
    [No Abstract]   [Full Text] [Related]  

  • 3. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 4. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
    Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
    [No Abstract]   [Full Text] [Related]  

  • 6. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
    Tan F; Shi Y; Wang Y; Ding L; Yuan X; Sun Y
    Future Oncol; 2015; 11(3):385-97. PubMed ID: 25675121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 8. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
    Garfield DH
    J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
    [No Abstract]   [Full Text] [Related]  

  • 10. Irreversible kinase inhibitors gain traction.
    Sanderson K
    Nat Rev Drug Discov; 2013 Sep; 12(9):649-51. PubMed ID: 23989776
    [No Abstract]   [Full Text] [Related]  

  • 11. Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Van Sebille YZ; Gibson RJ; Wardill HR; Bowen JM
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):152-6. PubMed ID: 27035390
    [No Abstract]   [Full Text] [Related]  

  • 12. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
    Twombly R
    J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
    [No Abstract]   [Full Text] [Related]  

  • 13. Next generation tyrosine kinase inhibitor (TKI): afatinib.
    Kumar S; Agrawal R
    Recent Pat Anticancer Drug Discov; 2014; 9(3):382-93. PubMed ID: 24844234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
    Forde PM; Ettinger DS
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):528-32. PubMed ID: 26351816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New kinase inhibitor approved for metastatic lung cancer.
    Thompson CA
    Am J Health Syst Pharm; 2013 Aug; 70(16):1363. PubMed ID: 23903470
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib or docetaxel in advanced non-small-cell lung cancer.
    Cullen M; Thatcher N
    Lancet; 2008 Nov; 372(9652):1785-6. PubMed ID: 19027472
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
    Garfield D
    J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.